ATE427302T1 - Arylsulphonamidderivat und deren verwendung als b1-bradykinin rezeptor antagonisten - Google Patents

Arylsulphonamidderivat und deren verwendung als b1-bradykinin rezeptor antagonisten

Info

Publication number
ATE427302T1
ATE427302T1 AT03760017T AT03760017T ATE427302T1 AT E427302 T1 ATE427302 T1 AT E427302T1 AT 03760017 T AT03760017 T AT 03760017T AT 03760017 T AT03760017 T AT 03760017T AT E427302 T1 ATE427302 T1 AT E427302T1
Authority
AT
Austria
Prior art keywords
alkyl
arylsulphonamide
derivative
receptor antagonists
bradykinin receptor
Prior art date
Application number
AT03760017T
Other languages
English (en)
Inventor
Martine Barth
Michel Bondoux
Pierre Dodey
Christine Massardier
Jean-Michel Luccarini
Original Assignee
Fournier Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Sa filed Critical Fournier Lab Sa
Application granted granted Critical
Publication of ATE427302T1 publication Critical patent/ATE427302T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
AT03760017T 2002-06-14 2003-06-12 Arylsulphonamidderivat und deren verwendung als b1-bradykinin rezeptor antagonisten ATE427302T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0207387A FR2840897B1 (fr) 2002-06-14 2002-06-14 Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique

Publications (1)

Publication Number Publication Date
ATE427302T1 true ATE427302T1 (de) 2009-04-15

Family

ID=29595270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03760017T ATE427302T1 (de) 2002-06-14 2003-06-12 Arylsulphonamidderivat und deren verwendung als b1-bradykinin rezeptor antagonisten

Country Status (14)

Country Link
US (1) US7361687B2 (de)
EP (1) EP1521744B1 (de)
JP (1) JP4411204B2 (de)
AT (1) ATE427302T1 (de)
AU (1) AU2003255668A1 (de)
CA (1) CA2489209C (de)
DE (1) DE60326957D1 (de)
DK (1) DK1521744T3 (de)
ES (1) ES2325154T3 (de)
FR (1) FR2840897B1 (de)
HK (1) HK1073659A1 (de)
PT (1) PT1521744E (de)
SI (1) SI1521744T1 (de)
WO (1) WO2003106428A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
DE102006039003A1 (de) * 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
WO2008153967A1 (en) * 2007-06-08 2008-12-18 Contec Therapeutics, Inc. Bk1 antagonist conjugates
EP2025675A1 (de) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
EP2025673A1 (de) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
WO2009021758A1 (de) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Arylsulfonamide mit analgetischer wirkung
CA2696302A1 (en) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh New compounds
WO2009021944A1 (de) 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Neue verbindungen
EP2025668A1 (de) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
JP2011512329A (ja) * 2008-02-06 2011-04-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有効な鎮痛剤としてのアリールスルホンアミド
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2316820A1 (de) 2009-10-28 2011-05-04 Dompe S.p.A. Als Bradykinin-Rezeptorantagonisten nützliche 2-Arylpropionamid-Derivate und pharmazeutische Zusammensetzungen damit
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR084193A1 (es) * 2010-12-09 2013-04-24 Fovea Pharmaceuticals Dosificaciones de derivados de arilsufonamida
AR084194A1 (es) * 2010-12-09 2013-04-24 Fovea Pharmaceuticals Derivados de arilsulfonamida para la prevencion o el tratamiento de trastornos oftalmologicos especificos
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
PT2813502T (pt) * 2013-06-14 2017-04-06 Dompé Farm S P A Antagonistas do recetor da bradicinina e composições farmacêuticas que os contêm
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP4233840A3 (de) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Kombinationen aus linagliptin und metformin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT84170B (pt) 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
PT84171B (pt) 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados das n alfa-aril-sulfonilamiminoacil-p- -amidinofenil-alaninamidas, bem como dos seus derivados de sintese e das composicoes farmaceuticas que os contem
WO1992016549A1 (de) 1991-03-18 1992-10-01 Pentapharm Ag Para-substituierte phenylalanin-derivate
DE4206858A1 (de) 1992-03-05 1993-09-09 Behringwerke Ag Glycopeptid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
FR2701480B1 (fr) 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
FR2735128B1 (fr) 1995-06-07 1997-07-25 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, leur procede de preparation et utilisation en therapeutique.
FR2743073B1 (fr) 1995-12-29 1998-02-20 Fournier Ind & Sante Nouveaux composes de 1-benzenesulfonylpyrrolidine, procede de preparation et utilisation en therapeutique
FR2743562B1 (fr) 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
FR2751650B1 (fr) * 1996-07-24 1998-10-09 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
FR2756562B1 (fr) 1996-12-04 1999-01-08 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
FR2765222B1 (fr) 1997-06-27 1999-12-31 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
EP1137661A1 (de) 1998-12-10 2001-10-04 F. Hoffmann-La Roche Ag Procollagen c-proteinase inhibitoren
GB9913079D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
FR2819254B1 (fr) * 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
JP4411204B2 (ja) 2010-02-10
AU2003255668A1 (en) 2003-12-31
CA2489209A1 (fr) 2003-12-24
HK1073659A1 (en) 2005-10-14
JP2005535613A (ja) 2005-11-24
CA2489209C (fr) 2011-08-02
EP1521744B1 (de) 2009-04-01
SI1521744T1 (sl) 2009-08-31
AU2003255668A8 (en) 2003-12-31
DK1521744T3 (da) 2009-07-13
WO2003106428A8 (fr) 2004-05-06
ES2325154T3 (es) 2009-08-27
WO2003106428A1 (fr) 2003-12-24
PT1521744E (pt) 2009-07-01
US7361687B2 (en) 2008-04-22
FR2840897A1 (fr) 2003-12-19
DE60326957D1 (de) 2009-05-14
FR2840897B1 (fr) 2004-09-10
US20060084699A1 (en) 2006-04-20
EP1521744A1 (de) 2005-04-13

Similar Documents

Publication Publication Date Title
ATE427302T1 (de) Arylsulphonamidderivat und deren verwendung als b1-bradykinin rezeptor antagonisten
NO20062031L (no) Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media
DK1490342T3 (da) Disubstituerede pyrazolylcarboxanilider
JP2004516293A5 (de)
DE60304587D1 (de) Chinolyl-propylpiperidinderivate und deren verwendung als antimikrobielles mittel
NO20072690L (no) Benzenforbindelser med 2 eller flere substituenter
ATE203747T1 (de) 5-azabicyclo(3.1.0.)hexylalkyl-2-piperidone und - glutarimide als neurokinin receptor antagonisten.
DE50009239D1 (de) Stabile salze neuartiger derivate von 3,3-diphenylpropylaminen
CO5670367A2 (es) Derivados de acido fenoxiacetico
HUP0101204A2 (hu) HIV-gátló pirimidinszármazékok és a vegyületeket tartalmazó gyógyászati készítmények
EA200401172A1 (ru) Производные n-[фенил(пиперидин-2-ил)метил]бензамида, способ их получения и их применение в терапии
ATE383338T1 (de) N-(phenyl(piperidin-2-yl)methyl)benzamid-deriva e,verfahren zu deren herstellung und ihre therapeutische verwendung
DE69231445D1 (de) Triazole enthaltende antifungizide mittel
EA199901102A1 (ru) Производные азетидинилпропилпиперидина, промежуточные соединения и применение в качестве антагонистов тахикинина
KR920006322A (ko) 벤젠, 피리딘 및 피리미딘 유도체
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
HRP20030610B1 (en) Process for the preparation of mesylates of piperazine derivatives
ATE308518T1 (de) Indolderivate und deren verwendung als liganden der receptoren cb2
MX9205221A (es) Broncodilatadores antimuscarinicos
ATE446948T1 (de) Alpha-ketoamidderivativ, herstellungsverfahren und verwendung davon
ATE388945T1 (de) Benzoxazolderivate und deren verwendung als adenosinrezeptorliganden
DK1603877T3 (da) Nye aminopyridinderivater som mGIuR5 antagonister
DE50313047D1 (de) Carboxyalkoxy-substituierte acyl-carboxyphenyl-harnstoffderivate, verfahren zu ihre herstellung und ihre verwendung als arzneimittel
GT200000024A (es) Compuestos de 1, 2, 3, 4 - tetrahidro - 1 - naftalenamina utiles en terapia.
DE60327932D1 (de) Anthranyl-derivate mit anti-cholecystokinin-aktivität (anti-cck-1) verfahren zu deren herstellung und deren pharmazeutische anwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1521744

Country of ref document: EP